{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-025725","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2024-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.082998+00:00","generated_at":"2026-05-31T23:54:54.815363+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cassava discloses potential unblinding in Phase 2b study; collaborator indicted by DOJ","bullets":["DOJ indicted Dr. Wang for allegedly causing false statements to NIH about simufilam; company terminated his consulting.","Internal investigation found senior employee may have unblinded Dr. Wang to some Phase 2b participants before bioanalysis.","Reported Phase 2b CANTAB analysis excluded ~42% of subjects for episodic memory; results reflect smaller analysis set.","Phase 3 trials fully enrolled (~1,900 patients), remain blinded; independent firms will handle bioanalysis."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-025725","json":"https://secwatch.observer/filing/0001493152-24-025725.json","markdown":"https://secwatch.observer/filing/0001493152-24-025725.md","text":"https://secwatch.observer/filing/0001493152-24-025725.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000149315224025725/0001493152-24-025725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000149315224025725/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:54:54.815363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}